Gene therapies are expensive because they require advanced biotechnology infrastructure, highly specialized engineering processes, and personalized manufacturing systems. Research and development, clinical trials, genetic engineering technologies, and custom production procedures all contribute to high costs. Access to these treatments remains a major challenge, particularly in low- and middle-income countries.